

44th Annual J.P. Morgan Healthcare Conference

January 2026



Disclaimer

This presentation has been prepared by Genus plc ("Genus" or "the Company") and has not been independently verified. Genus is solely responsible for the contents of this document and has taken all reasonable care to ensure that the facts stated herein are true and accurate in all material respects and that there are no material facts the omission of which would make misleading any statement in this document whether of fact or opinion.

While the information contained in this presentation has been provided in good faith, neither the Company, nor any of their advisers, representatives, officers, agents or employees makes any representation, warranty or undertaking, express or implied, in respect of this presentation and no responsibility or liability is accepted by any of them as to the accuracy, completeness or reasonableness of the information provided. The issue of this presentation to the recipient does not create any obligation on the part of the issuer to provide the recipient access to any additional information or to update this presentation or any additional information or to correct any inaccuracies in this presentation or any additional information which may become apparent. The recipient should conduct its own investigation into the Company and of any other information contained in the presentation.

This presentation is for information purposes only and does not constitute, and shall not be interpreted as, either an offer for sale, prospectus, invitation to subscribe for shares or debentures in the Company, or as the basis of a contract.

This presentation has been prepared on the basis that it will only be made available to investment professionals and is thereby exempt from the provisions of s21 of the Financial Services and Markets Act 2000.



Jorgen Kokke

Group Chief Executive Officer

- Appointed Genus CEO on July 1, 2023
- Deep experience in the international food and agriculture sectors
- 14 years in global leadership roles at Ingredion Incorporated, most recently as President, Americas



Anand Date

Investor Relations & Sustainability Director

- Joined Genus in September 2023
- CFA Charterholder
- Strong financial services background; 15 years in sell-side equity research at Deutsche Bank and HSBC

Our vision

“

“Pioneering animal genetic improvement to sustainably nourish the world”



What Genus does



We produce and sell elite animal genetics to farmers.

Our genetics constitute less than 2% of a farmer's cost base



Our animals exhibit valuable traits such as increased feed conversion, growth rates and robustness



This helps our customers raise healthier animals that produce more high-quality protein per unit of input



Our products therefore improve farmer profitability and reduce the environmental impact of animal protein production


How Genus does it

Our goal is to drive continuous genetic improvement in our proprietary elite herds


- We score each animal on observable (phenotypic) and genetic (genomic) traits
- These scores drive each animal's Estimated Breeding Value ("EBV"); the higher the EBV, the greater the genetic potential
- Animals with the highest EBVs are bred together to drive genetic improvement in the next generation of our elite animals
- Additionally, we are pioneering the use of precision gene editing technology to solve the most difficult disease challenges facing animal protein producers today

△ Genetic Improvement

$$\frac{\text{Selection Intensity} \times \text{Selection Accuracy} \times \text{Genetic Variation}}{\text{Generation Length}}$$



Market Leading Positions In Porcine & Bovine



Pig Improvement Company


Revenue
£363m

Adj. Op.
Profit £112m

Margin¹
27.6%

Global #1

- Best-in-class Porcine Genetics
- Royalty payment model → annual recurring revenue and high customer retention
- Significant white space
- Very high barriers to entry
- Transformative growth opportunities



ABS Global

Revenue
£308m

Adj. Op.
Profit £20m

Margin¹
6.3%

Global #2

- Leading Dairy Genetics
- Best-in-class Beef Genetics
- One of only two players with commercial sexing technology
- Value Acceleration Programme driving progress to double digit margins

¹: Adj. Operating Margin excludes joint ventures

Supported By Durable Growth Drivers



Growing demand
for animal protein

Resilient global
growth in animal
protein consumption



Win market
share

Win and Grow with our
customers

Gain share within
customers



Transformative
growth
opportunities

PRRS Resistant
Pig

PIC China

Supported By Durable Growth Drivers



Growing demand for animal protein

0.4% to 1.9%

Expected annual growth in global consumption of pigmeat, beef and milk to 2034¹



Win market share

Win and Grow with our customers

Gain share within customers

50%

Reduction in the number of U.S. hog farms over the last 30 years. Our customers are consolidating and taking share

19 of the Top 20

U.S. pork producers that we already work with. Over time, our genetic performance drives share gains within our customers' businesses



Transformative growth opportunities

PRRS Resistant Pig

PIC China

Double


Potential increase in PIC profitability as we commercialise our pioneering porcine gene edit

25

25 new royalty customers won in China in the last two years of which 3 are Top 5 producers

¹: UN Food & Agricultural Organization forecasts


An Established Royalty Revenue Model




- **Royalty revenue model:** PIC supplies physical product at cost and is paid a royalty on an ongoing basis
- 3-5 years contracts with high customer retention
- High penetration (>80% of volumes) of royalty model
- Very high drop through to operating profit
- Decouples profit from commodity pork prices
- Underpins forward visibility and profit growth

Strong Group Financial Performance

Adjusted Operating Profit £m
(actual currency, inc. JVs)



Free Cash Flow¹ £m



Return On Adjusted Invested Capital %




■ PIC China Adjusted Operating Profit

■ Group Adjusted Operating Profit ex PIC China

¹: Free Cash Flow is net of capital expenditure, lease repayments and exceptional items and defined in the Group's Annual Report

Significant Investment in R&D

Genus research and product development
% of Genus revenue



>10%

Genus invests more than 10% of revenue on research and product development

~80%


Invested in driving continuous genetic improvement in our elite herds

~20%

Invested in breakthrough R&D in **Gene Editing** (e.g. PRRS Resistant Pig), **Sexing Technology** and **Reproductive Biology**

Two Transformative Growth Opportunities To Come

Opportunity 1: PIC China




- China represents a very significant opportunity for PIC
- PIC has the product, team and supply chain to succeed in China, as it is doing in the rest of the world
- Penetration is accelerating: 25 new Chinese royalty customers won in the last 2 years

- Transformational Joint Venture creation with Beijing Capital Agribusiness ("BCA"), a leading state-backed agribusiness
- Best platform to further accelerate the growth of PIC China and introduce PRP to Chinese customers
- Completion expected in CY26; Genus to receive \$160m

1: Porcine Reproductive and Respiratory Syndrome

Two Transformative Growth Opportunities To Come

Opportunity 2: PRRS¹ Resistant Pig ("PRP")



- PRRS is a devastating endemic disease causing severe respiratory distress, anorexia, stillborn births and death
- Estimated PRRS costs ~\$1.2bn per annum in US alone
- Genus has developed a pioneering gene edit which utilises CRISPR Cas9 technology to remove the PRRS binding site
- Gene edited pigs exhibit resistance to PRRS strains with no other impact on the pig
- PRP improves animal welfare and reduces antibiotic usage, whilst delivering significant value to the pork value chain

1: Porcine Reproductive and Respiratory Syndrome

Two Transformative Growth Opportunities To Come


Opportunity 2: PRRS¹ Resistant Pig ("PRP")



Landmark U.S. FDA approval granted in April 2025

Key regulatory approvals being sought in Mexico, Canada, Japan and China

PRP has the potential to double PIC's profit



1: Porcine Reproductive and Respiratory Syndrome

Our Strategic Priorities



01. Continued growth in porcine, accelerated porcine JV in China

PIC ex-China; strong royalty revenue and adjusted operating profit growth

PIC China: Accelerated porcine joint venture formation in China with BCA acquiring 51% equity stake for \$160m



02. Successfully launch our PRP gene edit and deliver attractive returns from R&D

U.S. FDA: Landmark PRP gene edit approval received in April 2025

Good continuing progress with regulators, in Canada, Mexico, Japan, China and other jurisdictions



03. Drive greater value from bovine

VAP initiatives driving 190 basis point margin improvement in FY25

Committed to delivering a double-digit margin in the medium term

Why Invest In Genus

01

Growing and resilient end-markets

Increasing global demand for animal protein

02

Embedded positions, leading products

World-class genetics, a well-invested, global supply chain and wrap-around holistic services

03

Significant white space

Significant addressable market growth through customers gaining market share, capturing more genetic benefit and increasing their use of data and technology

04

Two Transformative growth opportunities

PIC China and the PRRS¹ Resistant Pig

05

Defensible intellectual property

Elite germplasm, substantial proprietary data, patents in gene editing and reproductive biology

¹: Porcine Reproductive and Respiratory Syndrome

Q&A